ArticleCancer cell international2014
Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease.
Article in Cancer cell international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 38 citations in OpenAlex.
- Article
- Article
- Targeting TYROBP to influence the immune microenvironment and osteogenic differentiation of mesenchymal stem cells.Journal of orthopaedic surgery and research · 2025Article
- Complement C3a promotes the formation of osteoclasts by inhibiting Sirt1 to activate the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma.Journal of translational medicine · 2025Article
- Oversecretion of CCL3 by Irradiation-Induced Senescent Osteocytes Mediates Bone Homeostasis Imbalance.Cells · 2025Article
- Systemic Inflammatory Regulators Associated with Osteoporosis: A Bidirectional Mendelian Randomization Study.Calcified tissue international · 2024Article
- The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease.International journal of molecular sciences · 2023Review
- CCL3 in the bone marrow microenvironment causes bone loss and bone marrow adiposity in aged mice.JCI insight · 2023Article
- Leveraging mice with diverse microbial exposures for advances in osteoimmunology.Frontiers in endocrinology · 2023Article
- Osteogenic Efficacy of Human Trophoblasts-Derived Conditioned Medium on Mesenchymal Stem Cells.International journal of molecular sciences · 2022Article
- Pathogenesis and Treatment of Myeloma-Related Bone Disease.International journal of molecular sciences · 2022Review
- The Rising Era of "Immunoporosis": Role of Immune System in the Pathophysiology of Osteoporosis.Journal of inflammation research · 2022Review
- Intermittent Hypoxic Therapy Inhibits Allogenic Bone-Graft Resorption by Inhibition of Osteoclastogenesis in a Mouse Model.International journal of molecular sciences · 2021Article
- Myeloma Bone Disease: The Osteoblast in the Spotlight.Journal of clinical medicine · 2021Review
- Management of Myeloma Bone Lesions.International journal of molecular sciences · 2021Review
- Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background.International journal of molecular sciences · 2021Review
- Modulating macrophage activities to promote endogenous bone regeneration: Biological mechanisms and engineering approaches.Bioactive materials · 2021Review
- Multiple myeloma-derived exosomes inhibit osteoblastic differentiation and improve IL-6 secretion of BMSCs from multiple myeloma.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2020Article
- Chemokines in Physiological and Pathological Bone Remodeling.Frontiers in immunology · 2019Review
- B cells inhibit bone formation in rheumatoid arthritis by suppressing osteoblast differentiation.Nature communications · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple myeloma is a hematologic malignancy characterized by the accumulation of monoclonal plasma cells in the bone marrow. A common manifestation of the disease is myeloma bone disease (MBD), which is caused by increased osteoclastic bone resorption and decreased bone formation. The chemokine cytokine ligand 3 (CCL3) is a pro-inflammatory protein and chemokine that stimulates osteoclasts in MBD. However, little is known about the effect of CCL3 on osteoblasts (OB).
methodsThe OBs are induced from patients with MBD and healthy donors, cultured in vitro, and identified by histochemistry. The effects of CCL3 and CCL3 antibody on the OBs in vitro are observed. The CCL3 receptor (CCR1), osteocalcin (OCN), runt-related transcription factor 2 (Runx2), and osterix (Osx) are detected using flow cytometry, enzyme-linked immunosorbent assay, and real-time PCR.
resultsProliferation and osteogenic potential of the OB in patients with MBD are suppressed. Moreover, the CCR1 expression is significantly higher in patients with MBD than in normal controls. The OCN level, quantity of calcium nodules, and Runx2 and Osx levels decrease after CCL3 stimulation, which indicates that CCL3 inhibits OB function. Furthermore, CCL3 antibody partially restores OB activity through the upregulation of the OCN, Runx2, and Osx.
conclusionsCCL3 contributes to the OB/OC imbalance by inhibiting OB differentiation and function in MBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.